# Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer

> **NCT01980277** · PHASE1,PHASE2 · TERMINATED · sponsor: **Institut Paoli-Calmettes** · enrollment: 68 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** LY2780301 + paclitaxel

## Key facts

- **NCT ID:** NCT01980277
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2017-05
- **Final completion:** 2018-12-12
- **Target enrollment:** 68 (ESTIMATED)
- **Why stopped:** Drug development stopped
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01980277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01980277, "Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01980277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*